U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H25NO3
Molecular Weight 279.3752
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOXISYLYTE

SMILES

CC(C)c1cc(c(C)cc1OCCN(C)C)OC(=O)C

InChI

InChIKey=VRYMTAVOXVTQEF-UHFFFAOYSA-N
InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3

HIDE SMILES / InChI

Molecular Formula C16H25NO3
Molecular Weight 279.3752
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://books.google.ru/books?id=S4GJio79XOUC&pg=PA97&lpg=PA97&dq=MOXISYLYTE+%09Withdrawal&source=bl&ots=dzBbL_E8c0&sig=r1pfUZ1LhFGihzzNswfGr7f38Mg&hl=ru&sa=X&ved=0ahUKEwjNlJeazZnOAhWJnBoKHZRoC3YQ6AEIVzAJ#v=onepage&q=MOXISYLYTE%20%09Withdrawal&f=false http://www.ncbi.nlm.nih.gov/pubmed/1475074

Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction, also was studied, that this drug may be useful to treat ocular disorders such as diabetic retinopathy. It is an alpha1-adrenergic antagonist. Was developed for self-injection therapy in France and marketed in several European countries as Icavex. In the spring 2005 the manufacturer of Icavex decided to withdraw this drug from Europe market, presumable due to its low market shares.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effect of thymoxamine and pilocarpine on the depth of the anterior chamber.
1980 Oct
Effects of thymoxamine and its metabolites on clonidine-induced hypotension and bradycardia in rats.
1982 Jul
Ergotamine-induced peripheral ischaemia reversed by oral thymoxamine hydrochloride.
1986 Jan
Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte.
2000 Mar 15
[Intracavernous injections in the treatment of erectile dysfunction in spinal cord injured patients: experience with 36 patients].
2001 Feb
The esterase-like activity of serum albumin may be due to cholinesterase contamination.
2001 Oct
Synergistic effects of sildenafil on relaxation of rabbit and rat cavernosal smooth muscles when combined with various vasoactive agents.
2001 Oct
Assessment of the intrinsic urethral sphincter component function in postprostatectomy urinary incontinence.
2002
Alpha(1L)-, but not alpha(1H)-, adrenoceptor antagonist prevents allergic bronchoconstriction in guinea pigs in vivo.
2002 Sep 27
Unoprostone isopropyl ester darkens iris color in pigmented rabbits with sympathetic denervation.
2003 Aug
Electroacupuncture-induced pressor and chronotropic effects in anesthetized rats.
2006 Jan 30
Noradrenergic control of arginine vasopressin release from the ewe hypothalamus in vitro: sensitivity to oestradiol.
2008 Apr
Oral vasodilators for primary Raynaud's phenomenon.
2008 Apr 16
Noradrenergic control of GnRH release from the ewe hypothalamus in vitro: sensitivity to oestradiol.
2008 Dec
Raynaud's phenomenon (primary).
2008 Dec 16
Raynaud's phenomenon (secondary).
2008 Sep 26
Effects of adrenergic agents on the expression of zebrafish (Danio rerio) vitellogenin Ao1.
2009 Jul 1
Patents

Sample Use Guides

In Vivo Use Guide
Intracavernous injection of moxisylyte at 10, 20 or 30 mg can induce an erection adequate for intercourse in most of the patients
Route of Administration: Other
In Vitro Use Guide
Moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue was investigated and compared with other alpha-adrenergic antagonists. Moxisylyte produced a concentration-dependent relaxation of a norepinephrine-induced (1 x 10(-5) M) contraction of the corpus cavernosum tissue. Pretreatment with 1 x 10(-6) M doses of moxisylyte reduced competitively the norepinephrine-induced contraction
Substance Class Chemical
Created
by admin
on Sat Jun 26 01:23:44 UTC 2021
Edited
by admin
on Sat Jun 26 01:23:44 UTC 2021
Record UNII
PW8QYA7KI0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOXISYLYTE
INN   MI   WHO-DD  
INN  
Official Name English
MOXISYLYTE [WHO-DD]
Common Name English
MOXISYLYTE [MI]
Common Name English
CARLYTENE
Brand Name English
(2-(4-ACETOXY-2-ISOPROPYL-5-METHYLPHENOXY)ETHYL)DIMETHYLAMINE
Systematic Name English
6-ACETOXYTHYMOL 2-(DIMETHYLAMINO)ETHYL ETHER
Common Name English
THYMOXAMINE
Common Name English
MOXISYLYTE [INN]
Common Name English
Classification Tree Code System Code
WHO-ATC G04BE06
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
NCI_THESAURUS C29713
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
WHO-VATC QC04AX10
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
WHO-VATC QG04BE06
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
WHO-ATC C04AX10
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
Code System Code Type Description
EVMPD
SUB09090MIG
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
PUBCHEM
4260
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
RXCUI
10561
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY RxNorm
FDA UNII
PW8QYA7KI0
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
INN
1538
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
NCI_THESAURUS
C87584
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
MESH
D013948
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
MERCK INDEX
M7648
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
200-204-1
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
ChEMBL
CHEMBL159226
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
EPA CompTox
54-32-0
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
DRUG BANK
DB09205
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
DRUG CENTRAL
1855
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
CAS
54-32-0
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
WIKIPEDIA
Moxisylyte
Created by admin on Sat Jun 26 01:23:44 UTC 2021 , Edited by admin on Sat Jun 26 01:23:44 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY